Windecker, Stephan

Predictors of functional decline in elderly patients undergoing transcatheter aortic valve implantation (TAVI)

Schoenenberger, A. W., Stortecky, S., Neumann, S., Moser, A., Juni, P., Carrel, T., Huber, C., Gandon, M., Bischoff, S., Schoenenberger, C.-M., et al. (2013) · European Heart Journal

Cardiac Valve Diseases and TreatmentsFrailty in Older Adults

Cited by 299

Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018

Fanaroff, A. C., Califf, R. M., Windecker, S., Smith, S. C., & Lopes, R. D. (2019) · JAMA

Clinical practice guidelines implementationHealth Sciences Research and Education

Cited by 228

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

Landmesser, U., Chapman, M. J., Stock, J. K., Amarenco, P., Belch, J. J. F., Borén, J., Farnier, M., Ference, B. A., Gielen, S., Graham, I., et al. (2018) · European Heart Journal

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 200

Coronary artery disease severity and aortic stenosis: clinical outcomes according to SYNTAX score in patients undergoing transcatheter aortic valve implantation

Stefanini, G. G., Stortecky, S., Cao, D., Rat-Wirtzler, J., O'Sullivan, C. J., Gloekler, S., Buellesfeld, L., Khattab, A. A., Nietlispach, F., Pilgrim, T., et al. (2014) · European Heart Journal

Cardiac Valve Diseases and TreatmentsAortic Disease and Treatment Approaches

Cited by 190

Hypertrophic cardiomyopathy detection with artificial intelligence electrocardiography in international cohorts: an external validation study

Siontis, K. C., Wieczorek, M. A., Maanja, M., Hodge, D. O., Kim, H.-K., Lee, H.-J., Lee, H., Lim, J., Park, C. S., Ariga, R., et al. (2024) · European Heart Journal - Digital Health

ECG Monitoring and AnalysisCardiomyopathy and Myosin Studies

Cited by 44

Eligibility for PCSK9 inhibitors according to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines after acute coronary syndromes

Gencer, B., Koskinas, K. C., Räber, L., Karagiannis, A., Nanchen, D., Auer, R., Carballo, D., Carballo, S., Klingenberg, R., Heg, D., et al. (2017) · Journal of the American Heart Association

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 35

Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial

Koskinas, K. C., Windecker, S., Buhayer, A., Gencer, B., Pedrazzini, G., Mueller, C., Cook, S., Muller, O., Matter, C. M., Räber, L., et al. (2018) · Clinical Cardiology

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 26

1-Month or 3-Month DAPT in Women and Men at High Bleeding Risk Undergoing PCI

Kunadian, V., Gitto, M., Vogel, B., Sartori, S., Angiolillo, D. J., Bhatt, D. L., Chehab, B. M., Feng, Y., de la Torre Hernandez, J. M., Krucoff, M. W., et al. (2025) · JACC: Cardiovascular Interventions

Antiplatelet Therapy and Cardiovascular DiseasesCoronary Interventions and Diagnostics

Cited by 7